Duke, UNC receive hefty NIH awards
The University of North Carolina at Chapel Hill and Duke University are both recipients of multi-million-dollar awards from the National Institutes of Health to accelerate the benefits of clinical and translational research for North Carolina patients.
UNC-Chapel Hill will partner with two institutions, RTI International for research and North Carolina A&T State University for planning and laboratory access, to use the NIH’s five-year, $54.6 million Clinical and Translational Science Award (CTSA).
The Duke Translational Medicine Institute has been awarded a five-year grant of more than $47 million to help speed biomedical research advances to patient care.
Duke was one of the original 12 CTSA grant recipients in 2006. The funds pay for critical needs within biomedical research, including biostatistical and regulatory expertise, technical support, biobank access, startup capital, and other essentials.
“Duke’s successful renewal of the CTSA means that now we can provide more resources for our scientists and clinicians as they work to translate laboratory discoveries into innovative treatments,” said Dr. Nancy C. Andrews, dean of the Duke School of Medicine, in a statement. “Federal funding is absolutely essential if we are going to improve how we care for patients in our country, so I am particularly pleased to see this level of funding from the NIH to support research.”
Launched in 2006, the NIH-led CTSA program has enabled research teams to speed discovery and advance science aimed at improving the nation’s health. Institutional CTSA awards are at the heart of the program, providing academic homes for translational sciences, according to the UNC release.
The program currently supports a consortium of about 60 academic medical institutions that is fostering team science, leveraging national resources and transforming the way biomedical research is conducted across the country.
At UNC-Chapel Hill, the grant will provide another five years of funding for the North Carolina Translational and Clinical Sciences (NC TraCS) Institute, which is now recognized as the central entity on UNC campus responsible for the advancement of clinical and translational research. Since its inception in 2008 as the home of UNC’s CTSA, NC TraCS has changed the clinical and translational research landscape at UNC and across the state, with outreach efforts touching each of North Carolina’s 100 counties.
UNC and its institution partners will research next-generation technologies to transform the nature of clinical research and practice, conduct comparative effectiveness studies to provide evidence of the benefits and or harms of tests and treatments, and discover new ways to accelerate drug development.
“Chapel Hill is a special place because of the collegiality of the faculty and the proximity of the health sciences schools — medicine, public health, pharmacy, nursing, dentistry, and social work — and the College of Arts and Sciences,” said William L. Roper, dean of the UNC School of Medicine, chief executive officer of UNC Health Care and vice chancellor for Health Affairs at UNC, in a statement. “But the new partnership with RTI, the growing partnership with N.C. A&T and our existing partnerships across the state truly enhance our ability to improve health for all North Carolinians.”